Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia
Background: Carrier screening for cystic fibrosis is not widely available in Australia, partly due to concerns regarding its cost-effectiveness. The benefit of information from pregnancy to pregnancy has not been widely considered in existing cost-effectiveness analyses.Methods: A decision tree was...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Elsevier
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/25772 |
| _version_ | 1848751801060294656 |
|---|---|
| author | Norman, Richard Van Gool, K. Hall, J. Delatycki, M. Massie, J. |
| author_facet | Norman, Richard Van Gool, K. Hall, J. Delatycki, M. Massie, J. |
| author_sort | Norman, Richard |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Background: Carrier screening for cystic fibrosis is not widely available in Australia, partly due to concerns regarding its cost-effectiveness. The benefit of information from pregnancy to pregnancy has not been widely considered in existing cost-effectiveness analyses.Methods: A decision tree was constructed estimating costs and outcomes from screening, including both initial and subsequent pregnancies. Effectiveness was expressed in terms of CF births averted. Costs were collected using a health service perspective. All costs and outcomes were discounted at 5% per annum.Results: Screening reduced the annual incidence of CF births from 34 to 14/100,000 births (an aggregate number of CF births of 100.9 and 41.9 respectively). In initial pregnancies, costs in the screening arm (A$16.6 million/100,000 births) exceed those in the non-screening arm (A $13.4 million/100,000 births). The incremental cost per CF birth in initial pregnancies is therefore approximately A$150,000. However, this was reversed for subsequent pregnancies, in that the pre-collected information reduces the incidence of CF in subsequent pregnancies at low additional costs.When aggregated, the results suggest screening is likely to be cost-saving.Conclusions: The introduction of national carrier screening for cystic fibrosis should be considered, as it is likely to reduce CF incidence at an acceptable (potentially negative) cost. |
| first_indexed | 2025-11-14T07:58:30Z |
| format | Journal Article |
| id | curtin-20.500.11937-25772 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:58:30Z |
| publishDate | 2012 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-257722017-09-13T15:22:40Z Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia Norman, Richard Van Gool, K. Hall, J. Delatycki, M. Massie, J. Screening Cost-effectiveness Australia Economic evaluation Cystic fibrosis Background: Carrier screening for cystic fibrosis is not widely available in Australia, partly due to concerns regarding its cost-effectiveness. The benefit of information from pregnancy to pregnancy has not been widely considered in existing cost-effectiveness analyses.Methods: A decision tree was constructed estimating costs and outcomes from screening, including both initial and subsequent pregnancies. Effectiveness was expressed in terms of CF births averted. Costs were collected using a health service perspective. All costs and outcomes were discounted at 5% per annum.Results: Screening reduced the annual incidence of CF births from 34 to 14/100,000 births (an aggregate number of CF births of 100.9 and 41.9 respectively). In initial pregnancies, costs in the screening arm (A$16.6 million/100,000 births) exceed those in the non-screening arm (A $13.4 million/100,000 births). The incremental cost per CF birth in initial pregnancies is therefore approximately A$150,000. However, this was reversed for subsequent pregnancies, in that the pre-collected information reduces the incidence of CF in subsequent pregnancies at low additional costs.When aggregated, the results suggest screening is likely to be cost-saving.Conclusions: The introduction of national carrier screening for cystic fibrosis should be considered, as it is likely to reduce CF incidence at an acceptable (potentially negative) cost. 2012 Journal Article http://hdl.handle.net/20.500.11937/25772 10.1016/j.jcf.2012.02.007 Elsevier unknown |
| spellingShingle | Screening Cost-effectiveness Australia Economic evaluation Cystic fibrosis Norman, Richard Van Gool, K. Hall, J. Delatycki, M. Massie, J. Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia |
| title | Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia |
| title_full | Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia |
| title_fullStr | Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia |
| title_full_unstemmed | Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia |
| title_short | Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia |
| title_sort | cost-effectiveness of carrier screening for cystic fibrosis in australia |
| topic | Screening Cost-effectiveness Australia Economic evaluation Cystic fibrosis |
| url | http://hdl.handle.net/20.500.11937/25772 |